Autolus Therapeutics plc (AUTL) Stock Forecast
AUTL analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.89 / 5 from 9 analysts
- Price target
- $8.72 average of analyst targets
- Upside to target
- +445.3% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.21
- 52-week range
- $1.21 – $2.54
AUTL analyst ratings
9 analystsNumber of analysts at each rating.
AUTL price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
AUTL earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.17 | −$0.22 | −$0.10 | −$0.30 | +44.4% | 6 |
| Current fiscal year (2026) | −$0.80 | −$0.97 | −$0.61 | −$1.08 | +25.9% | 8 |
| Next fiscal year (2027) | −$0.64 | −$0.97 | −$0.31 | −$0.80 | +20.3% | 8 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
AUTL revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $40.0M | $37.0M | $46.0M | +88.9% | 6 |
| Current fiscal year (2026) | $149.8M | $146.5M | $155.4M | +98.7% | 8 |
| Next fiscal year (2027) | $192.4M | $155.9M | $223.3M | +28.5% | 8 |
AUTL EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
AUTL revenue: reported and forecast
AUTL EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.21 | −$0.16 | −$0.16 | −$0.16 | −$0.17 | −20.0% | 6 up · 0 down |
| Current fiscal year (2026) | −$0.89 | −$0.77 | −$0.79 | −$0.79 | −$0.80 | −9.8% | 7 up · 1 down |
| Next fiscal year (2027) | −$0.61 | −$0.62 | −$0.63 | −$0.63 | −$0.64 | +5.4% | 3 up · 4 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
AUTL earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; AUTL beat in 4 of 12.
What analysts expect from AUTL
9 analysts cover Autolus Therapeutics; their consensus rating is strong buy (4.89 on a 1–5 scale, where 5 is a strong buy). The average price target is $8.72, 445.3% above the latest close of $1.60. Analysts expect earnings of −$0.80 per share for 2026, +25.9% from a year earlier. For 2027 the average estimate is −$0.64 per share on revenue of $192.4 million. Autolus Therapeutics beat the EPS estimate in 4 of the last 12 quarters.
Related: AUTL income statement, AUTL key metrics, AUTL chart. See the AUTL stock overview for the latest quote and news.
AUTL forecast FAQ
What is Autolus Therapeutics's price target?
The average analyst price target for Autolus Therapeutics is $8.72, 445.3% above the latest close of $1.60.
Is Autolus Therapeutics a buy, hold or sell?
Of 9 analysts covering Autolus Therapeutics, 8 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Autolus Therapeutics's EPS forecast?
Analysts forecast −$0.80 per share for 2026 (range −$0.97 to −$0.61); for 2027 the estimate is −$0.64.
What is Autolus Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $149.8 million, growth of 98.7%; for 2027 it is $192.4 million.
When does Autolus Therapeutics report earnings?
Autolus Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $-0.21.
Does Autolus Therapeutics usually beat earnings estimates?
Autolus Therapeutics reported EPS at or above the analyst estimate in 4 of the last 12 quarters.